
Cancer survival rates in England are continuing to improve, though many cancers still have an ‘extremely poor’ prognosis, according to …

Celgene has extended its collaboration with Sutro Biopharma and added a buyout option for the firm as the two companies …

As the possibility of a deal with Pfizer fades, AstraZeneca is continuing its argument for independence as a key cancer …

The global system for discovering new cancer drugs is ‘broken’ and failing to turn scientific advances into enough innovative new …

Cancer Research UK has launched its second citizen science game this year called ‘Reverse The Odds’ in an attempt to …

Swiss pharma giant Novartis has announced three of its executives are to leave the firm following deals with Lilly and …
NHS England is declaring new changes to the way the Cancer Drugs Fund operates in order to plug a major …

Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …

A Cancer Research UK study out today reveals that nearly half of all cancers in England are diagnosed at an …

Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …

Boehringer is hoping to expand its oncology pipeline with a new multi-million dollar pact for an investigational cancer vaccine. The …

A new type of cell therapy for cancer has become the first to be deemed by the UK government as …

NHS cancer services are in urgent need of investment and review, according to a new report commissioned by Cancer Research …

AZ’s MedImmune has entered into a clinical trial collaboration with US biotech firm Advaxis to help develop new cancer immunotherapies. …

Roche subsidiary Genentech is to pay around $1.7 billion for biotech firm Seragon Pharmaceuticals to secure its portfolio of potential …